Abstract
Opioid-induced bowel dysfunction, of which constipation is the most common aspect, is a major limiting factor in the use of opioids for pain management. The availability of an oral, long-acting formulation of oxycodone and naloxone represents a highly significant development in pain management. The combination of an opioid analgesic with an opioid antagonist offers reliable pain control with a significant reduction in the burden of opioid-induced constipation.
Keywords:
bowel; dysfunction; naloxone; opioid; quality of life.
MeSH terms
-
Administration, Oral
-
Analgesics, Opioid / administration & dosage
-
Analgesics, Opioid / adverse effects
-
Analgesics, Opioid / therapeutic use
-
Constipation / chemically induced
-
Constipation / prevention & control*
-
Delayed-Action Preparations
-
Drug Combinations
-
Humans
-
Naloxone / administration & dosage*
-
Naloxone / adverse effects
-
Naloxone / therapeutic use
-
Narcotic Antagonists / administration & dosage
-
Narcotic Antagonists / adverse effects
-
Narcotic Antagonists / therapeutic use
-
Oxycodone / administration & dosage*
-
Oxycodone / adverse effects
-
Oxycodone / therapeutic use
-
Pain / drug therapy*
Substances
-
Analgesics, Opioid
-
Delayed-Action Preparations
-
Drug Combinations
-
Narcotic Antagonists
-
oxycodone naloxone combination
-
Naloxone
-
Oxycodone